This week in Drug Discovery (29 June – 3 July)
News round-up for 29 June – 3 July by Bruno Quinney, Content Team at DDW.
This week, experts warn patients are being denied access to personalised cancer care. Cancer research is a theme elsewhere, with findings emerging from studies into a CAR T-cell therapy, lung cancer and breast cancer.
The top stories:
Patients denied personalised cancer care, study says
Health economists Dr Yufan Wang and Professor Haitham Tuffaha led a review into the value of theranostic nuclear medicine, an innovative frontier in cancer treatment, and concluded patients are being denied access because health systems struggle to assess its cost-effectiveness.
Read more…
CAR T-cell therapy selectively targets cancer mutations
A research effort led by University College London (UCL) and the University of Oxford engineered a CAR T-cell therapy which can reprogramme a patient’s own immune cells to target specific cells in the body.
Genetic mutations could be therapeutic target in lung cancer
Researchers have uncovered the genetic basis of multiple primary lung cancers, shedding light on potential therapeutic targets for treatment.
Read more…
Breast cancer patients profiled to determine drug efficacy
Researchers have identified which breast cancer patients should be treated with anthracyclines and who can safely avoid side effects of the drugs, a study shows.
New gene therapy could prevent epilepsy, study suggests
A new type of gene therapy that only activates when the brain is under stress could stop epilepsy before it fully develops, researchers say.
Read more…